TNFRSF17 and AL amyloidosis: For multiple myeloma patients who are BCMA-negative or have low BCMA expression, as well as those who experience BCMA-negative relapse due to target cell antigen immune escape after BCMA-targeted therapy, targeting GPRC5D offers a new therapeutic direction (6).